0
Translate Bio Banner Image

Translate Bio

  • Ticker TBIO
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Translate Bio Logo Image
  • 51-200 Employees
  • Based in Lexington, Massachusetts
Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. Their proprietary mRNA therapeutic platform (MRTTM) is designed to develop product candidates that deliver mRNA carrying instructions to produce intracellular, transmembrane and secreted proteins for therapeutic benefitMore. They believe that their MRTTM platform is applicable to a broad range of diseases caused by insufficient protein production or where production of proteins can modify disease, including diseases that affect the lung, liver, eye, central nervous system, lymphatic system and circulatory system. Their two lead programs are being developed as treatments for cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency.
REPORT RATINGS
4.0 / 5.0 (1)

Translate Bio reports have an aggregate usefulness score of 4.0 based on 1 reviews.

Translate Bio

Most Recent Annual Report

Translate Bio
MOST RECENT 2020 Annual Report

Older/Archived Annual Reports

Translate Bio Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!